Business

Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split

Reverse split approved at April 2026 Special Meeting of StockholdersShares of Jaguar Health common stock to begin trading on split-adjusted basis on April 30,

articleJaguar Health, Inc.April 27, 20265/company/jaguar-animal-health-inc/news/jaguar-health-granted-extension-until-may-15-2026-to-demonstrate-compliance-with-nasdaqs-bid-price-rule-company-announces-reverse-stock-split
Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split

About this update from Jaguar Health, Inc.

[{"type":"text","content":"Reverse split approved at April 2026 Special Meeting of StockholdersShares of Jaguar Health common stock to begin trading on split-adjusted basis on April 30, 2026 SAN FRANCISCO, CA / ACCESS Newswire / April 27, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) (\"Jaguar\" or the \"Company\") today announced that on April 24, 2026, the Company received formal notice that the Nasdaq Hearings Panel (the \"Panel\") has granted Jaguar an extension through May 15, 2026, to demonstrate compliance with the $1.00 bid price rule for continued listing on The Nasdaq Capital Market. To evidence compliance, the Company must report a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days on or before May 15, 2026. The Panel may defer a compliance determination for up to 20 business days.To support compliance with the $1.00 bid price rule, Jaguar today announced that it will effect a reverse stock split of its issued and outstanding voting common stock (\"Common Stock\"), at an exchange ratio of 1-for-35, on Thursday, April 30, 2026, (the \"Effective Date\"). The Company's Common Stock will begin trading on a split-adjusted basis when the market opens on the Effective Date and will remain listed on The Nasdaq Capital Market under the symbol \"JAGX.\" The new CUSIP number for the Company's Common Stock following the reverse stock split is 47010C862.The effectuation of the reverse stock split follows the approval of a proposal submitted to Jaguar stockholders at a Special Meeting of Stockholders (the \"Special Meeting\"). This proposal is described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Special Meeting filed with the Securities and Exchange Commission (the \"SEC\") on March 24, 2026. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at http://www.sec.gov. The proxy statement is also available on the Company's corporate website.When the reverse stock split becomes effective, every thirty-five (35) shares of the Company's Common Stock immediately prior to the Effective Date shall automatically be reclassified into one (1) share of Common Stock, without any change in the par value per share, and this change will be reflected on Nasdaq's website and other stock quote platforms. No fractional shares will be issued as a...

More updates from Jaguar Health, Inc.